Examining the safety, feasability and efficacy of a fentanyl-based protocol for neonates
Arctic Vision receives approval in Australia and Singapore for uveitic macular oedema treatment ARVN001
ARCATUS or ARVN001 was developed by Clearside Biomedical and commercialised in the Asia-Pacific region by Arctic Vision
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Home storage of anti-VEGF agents presents risk of temperature changes
The study findings suggest that patients should be educated about adherence to cold storage guidelines
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
Teva partners with Klinge Biopharma for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy
